Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipid phosphatase 5 (PLPP5)
- Target
- PLPP5
- Molecular classification
- Enzyme, Specifically, a phospholipid phosphatase acting on diacylglycerol pyrophosphate, phosphatidate, and lysophosphatidate, EC Number: 3.1.3.4 (phosphatidic acid phosphatase activity)
01
Overview
Phospholipid phosphatase 5 is a membrane-bound enzyme with broad substrate specificity, displaying magnesium-independent phosphatase activity. It predominantly catalyzes the dephosphorylation of diacylglycerol pyrophosphate to generate phosphatidate and can also act on other phospholipids. This biochemical activity affects lipid signaling and metabolism, linking PLPP5 to cellular processes such as signal transduction, actin dynamics (especially during phagocytosis), and possibly cancer suppression. Its physiological relevance is suggested by its involvement in benign and neoplastic gallbladder conditions, but disease associations and pharmacological targeting remain underexplored.
- Other names
- PLPP5PPAPDC1BDiacylglycerol pyrophosphate phosphatase-like 1 (DPPL1)HTPAPPhosphatidic acid phosphatase type 2 domain-containing protein 1BTesticular secretory protein Li 381810019D05Rik (mouse)2310022A04Rik (mouse)LOC683534 (mouse)
02
Mechanism of action
Drugs targeting PLPP5 (if developed) would likely act via inhibition or modulation of phospholipid dephosphorylation, altering lipid signaling and cellular processes
03
Biological functions
Phospholipid dephosphorylationSignal transductionLipid biosynthesis and degradationPotential role as a metastatic suppressor (suggested for hepatocellular carcinoma but not fully established in humans)Innate immune system
04
Disease associations
Gallbladder benign neoplasmGallbladder adenomaPutative cancer metastasis suppression (for hepatocellular carcinoma, mainly in experimental models)
05
Safety considerations
No notable safety concerns or therapeutic challenges have been published due to the lack of advanced clinical development or drugs targeting PLPP5Basic animal models indicate that knockout mice are viable, fertile, and generally normal
06
Interacting drugs
None identified in current literature or clinical databases
07
Biomarkers
None validated for patient selection or efficacy monitoring
Beyond the preview
Go deeper on Phospholipid phosphatase 5 (PLPP5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phospholipid phosphatase 5 (PLPP5).